Values as of: 2024-09-08
COMMON STOCK | Health Information Services |
Last Closing
USD 8.4Change
0.00 (0.00)%Market Cap
USD 5.79BVolume
400.00Analyst Target
N/AVerdict
Verdict
Currency: EUR
Country : Germany
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| L0T:F | GE HEALTHCARE TECH.INC. |
+1.53 (+1.93%) |
USD 35.91B |
| 2HE:F | Healthequity Inc |
-1.00 (-1.42%) |
USD 6.16B |
| 6HL0:F | R1 RCM Inc |
+0.10 (+0.79%) |
USD 5.45B |
| 9EH:F | Evolent Health Inc |
+0.40 (+1.46%) |
USD 3.16B |
| 1KJ:F | 10X GENOMICS DL -00001 |
+2.23 (+11.83%) |
USD 2.31B |
| 6JM:F | JMDC INC. |
N/A |
USD 1.93B |
| OC9:F | Omnicell Inc |
-1.80 (-4.50%) |
USD 1.78B |
| 19P:F | Phreesia Inc |
-0.20 (-0.92%) |
USD 1.26B |
| 4LL:F | Teladoc Inc |
+0.05 (+0.60%) |
USD 1.25B |
| 1XZ:F | Ping An Healthcare and Technol.. |
+0.02 (+1.57%) |
USD 1.21B |
N/A
| Market Performance vs. Industry/Classification (Health Information Services) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -42.47% | 24% | F | 11% | F | ||
| Dividend Return | 143.84% | 92% | A | 90% | A- | ||
| Total Return | 101.37% | 97% | N/A | 92% | A | ||
| Trailing 12 Months | |||||||
| Capital Gain | -52.27% | 24% | F | 11% | F | ||
| Dividend Return | 119.32% | 91% | A- | 87% | B+ | ||
| Total Return | 67.05% | 92% | A | 86% | B+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -20.02% | 20% | F | 10% | F | ||
| Dividend Return | 6.85% | 74% | C | 56% | F | ||
| Total Return | 26.87% | 92% | A | 85% | B | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 29.65% | 42% | F | 43% | F | ||
| Risk Adjusted Return | 23.12% | 76% | C+ | 52% | F | ||
| Market Capitalization | 5.79B | 97% | N/A | 80% | B- | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers median on a price to book value basis.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
